Cancer metastasis directly eradicated by targeted therapy with a modified Salmonella typhimurium

Area of Science:

• Oncology
• Microbiology
• Biotechnology

Background:

• Cancer metastasis is a primary cause of cancer-related mortality.
• Metastatic cancers are often resistant to conventional therapies.
• Targeted therapies are crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the efficacy of genetically modified Salmonella typhimurium (A1-R) as a targeted therapy for cancer metastasis.
• To evaluate the safety and effectiveness of A1-R in eradicating metastatic tumors in preclinical models.
• To demonstrate a novel, non-chemotherapeutic approach for treating metastatic disease.

Main Methods:

• Developed a genetically modified Salmonella typhimurium strain (A1-R) auxotrophic for arginine and leucine.
• Administered A1-R via lymphatic channels and tail vein injection to target lymph node and lung metastases in nude mice.
• Utilized fluorescent proteins (GFP and RFP) for real-time imaging of bacterial targeting and tumor response.

Main Results:

• Complete eradication of axillary lymph node metastasis (pancreatic cancer) and popliteal lymph node metastasis (fibrosarcoma) within 7-21 days.
• Successful eradication of lung metastasis (fibrosarcoma) in nude mice.
• No adverse effects observed in treated animals, indicating a favorable safety profile.

Conclusions:

• Genetically engineered Salmonella typhimurium (A1-R) demonstrates significant potential for treating cancer metastasis.
• This bacterial therapy offers a promising alternative to toxic chemotherapy for metastatic cancers.
• The study highlights the clinical feasibility of using engineered bacteria for targeted cancer treatment.